CeNeS Pharmaceutical Licenses Exclusive Japanese Rights for CNS7056 to Ono (Japan)
This article was originally published in PharmAsia News
Executive Summary
Biopharmaceutical company CeNeS Pharmaceuticals PLC has licensed the exclusive Japanese rights to its general anaesthetic and short-acting sedative, CNS-7056, to Ono Pharmaceutical Co Ltd. Cenes says it will receive upfront and milestone payments, as well as royalties on Ono's sales of CNS-7056. The company plans to start a phase I study in the US in the first half of 2008 and Ono will start a phase I study in Japan as early as the second half of 2008. (Click here for more
You may also be interested in...
Executives On The Move: Changes At The Top At Enzolytics, Dyne Therapeutics And Seres Therapeutics
Recent moves in the industry include new chief financial officers at LENZ Therapeutics and Botanix Pharmaceuticals, plus new chief medical officers at Vigil Neuroscience and Voyager Therapeutics.
Israel's Gamida Cell Survives By Selling To Lender
Having finally secured US approval for Omisirge, Gamida was hoping to bag a strategic partner for the cell therapy. A year on, no suitable partner has been identified and the firm is delisting from the NASDAQ and going private.
EU Regulatory Assessors Get AI Boost In Reaching Scientific Decisions
The European Medicines Agency is training scientific staff working for the European medicines regulatory network in how to use a new AI-powered search engine that allows them to easily retrieve information on regulatory precedents.